| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 56 |
| 1 | CYCLOPHOSPHAMIDE | 47 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 47 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 47 |
| 4 | DOXORUBICIN | 44 |
| 5 | ETOPOSIDE | 24 |
| 6 | PREDNISOLONE | 24 |
| 7 | PREDNISOLONE ORAL | 24 |
| 8 | PREDNISOLONE ORAL SOLUTION | 24 |
| 9 | CYTARABINE | 23 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | EPCORITAMAB-BYSP | 12 | 0.0090 |
| 1 | IDELALISIB | 13 | 0.0018 |
| 2 | ELRANATAMAB-BCMM | 1 | 0.0009 |
| 3 | DOXORUBICIN HYDROCHLORIDE | 23 | 0.0007 |
| 4 | IFOSFAMIDE FOR INJECTION | 14 | 0.0007 |
| 5 | BENDAMUSTINE HCL | 10 | 0.0006 |
| 6 | CARMUSTINE | 3 | 0.0006 |
| 7 | DOXORUBICIN | 44 | 0.0005 |
| 8 | THIOTEPA | 4 | 0.0004 |
| 9 | CYTARABINE | 23 | 0.0004 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 56 |
| 1 | Corticosteroid [EPC] | 51 |
| 2 | Alkylating Drug [EPC] | 49 |
| 3 | Platinum-based Drug [EPC] | 24 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 23 |
| 5 | Topoisomerase Inhibitor [EPC] | 20 |
| 6 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 12 |
| 7 | Folate Analog Metabolic Inhibitor [EPC] | 10 |
| 8 | Alkaloid [EPC] | 7 |
| 9 | Proton Pump Inhibitor [EPC] | 7 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 12 | 0.0030 |
| 1 | Alkaloid [EPC] | 7 | 0.0003 |
| 2 | Topoisomerase Inhibitor [EPC] | 20 | 0.0003 |
| 3 | Alkylating Drug [EPC] | 49 | 0.0002 |
| 4 | CD19-directed Chimeric Antigen Receptor [EPC] | 2 | 0.0002 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 56 | 0.0002 |
| 6 | Platinum-based Drug [EPC] | 24 | 0.0001 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 23 | 0.0001 |
| 8 | Phenothiazine [EPC] | 2 | 0.0001 |
| 9 | Xanthine Oxidase Inhibitor [EPC] | 7 | 0.0000 |